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Abstract: The purpose of this study was to investigate the influences of flunixin (FM) and tenoxicam (TN) on the pharmacokinetics
of florfenicol (FF) after coadministration in lipopolysaccharide (LPS)-induced endotoxemic rabbits. Fifteen male rabbits were used
in this study. FF (20 mg/kg), FM (2 mg/kg), and TN (1 mg/kg) were coadministered via intravenous injection to the animals. The
concentrations of FF were determined by high-performance liquid chromatography with diode-array detection from 0.08 to 12 h in
plasma. The plasma concentration-time profile of FF was described using a noncompartmental open model. In this study, terminal
half-life, area under the curve, mean residence time, and volume of distribution at steady state were significantly increased, whereas
total body clearance was decreased in coadministered groups. In conclusion, FM and TN have effects on the pharmacokinetics of FF in
coadministered endotoxemic rabbits. When FF is coadministered with FM and TN, it can be given at a dose of 20 mg/kg b.w. every 8 h
for treatment of infections caused by susceptible pathogens with a minimum inhibitory concentration (MIC) of ≤2 µg/mL or 12 h for
treatment of infections caused by susceptible pathogens with MIC of ≤1 µg/mL in critically ill rabbits. Further studies are necessary to
determine variations in dosage regimens.
Key words: Pharmacokinetics, florfenicol, rabbit, flunixin, tenoxicam, lipopolysaccharide

1. Introduction
Lipopolysaccharide (LPS) is an endotoxin present in
the cell walls of gram-negative bacteria and an immune
stimulant that induces the release of proinflammatory
cytokines. Administration of LPS causes the acute phase
response to be produced in the host and can also induce
multiorgan dysfunction, fever, hypotension, disseminated
intravascular coagulation, septic shock, and death (1,2).
LPS, Escherichia coli-derived, has been widely used to
cause an endotoxemic animal model in experiments (3,4).
Florfenicol (FF) is a synthetic broad-spectrum
antibiotic that acts against both gram-negative and
gram-positive organisms in the veterinary treatment
of infectious diseases. It is an antibiotic that belongs to
the chloramphenicol (CP) family, but it is used only in
animals. The drug inhibits peptidyl transferase activity
and affects bacterial protein synthesis at the 50S and
70S subunits ribosomes. Consequently, FF has more
antibacterial activity than other drugs (chloramphenicol
and thiamphenicol). Due to these advantages, FF has been
* Correspondence: feridekoc@yahoo.com
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supposed to be an ideal replacement for these two drugs in
veterinary clinics to treat bacterial diseases since the early
1990s (5). It has also been reported that FF has a protective
effect on acute lung injury induced by LPS in mice (6).
Flunixin meglumine (FM) and tenoxicam (TN) are
nonsteroidal antiinflammatory drugs (NSAIDs). They also
have analgesic and antipyretic properties. Antibiotics and
NSAIDs are usually coadministered in therapy (7,8). Drug
interaction is a common phenomenon in which a drug
affects the activity of another drug when coadministered.
This situation may be the result of various processes that
may include alterations in the pharmacokinetics of the
drug (9). Until now, the pharmacokinetic disposition of FF
has been extensively documented in healthy and infected
animal species only when FF was administered alone (10–
14). Interactions of FF with some drugs (anthelmintics,
polyether ionophores, and tylosin) have been reported
in previous studies (15–17). However, there has been no
pharmacokinetic report about the effects of FM and TN on
the pharmacokinetics of FF in endotoxemic rabbits.
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The purpose of this study was to determine the effects
of FM and TN on the pharmacokinetic disposition of
FF after intravenous coadministration in LPS-induced
endotoxemic rabbits.
2. Materials and methods
2.1. Animals
A total of 15 healthy, adult, male rabbits (New Zealand
White), approximately 6–12 months old and with a
body weight of 3.18 ± 0.15 kg, were used in the present
study. The rabbits were obtained from the Experimental
Research Center of Atatürk University. They were housed
there for 2 weeks before use. They were fed with pelleted
feed (antibacterial-free) and water ad libitum. Animal
experiments were performed in an ethically proper way,
following guidelines set by the Ethics Committee of
Atatürk University (Report No. 77/2014).
2.2. Drugs, chemicals, and instruments
FF (99.6% assay purity) and CP (99.7% assay purity)
analytical standards were purchased from Schering-Plough
(Segre, France). FF (Nuflor, 300 mg/mL, Sanofi), TN
(Oksamen-L, 20 mg, Mustafa Nevzat), and FM (Fluvil, 50
mg/mL, Vilsan) were sourced from Turkey. Ammonium
acetate, acetonitrile, and methanol were purchased from
J.T. Baker (Merck, Ari Medical, Erzurum, Turkey).
A high-performance liquid chromatography (HPLC)
Prominence LC-20 A Series with diode array detector
(DAD) and reverse phase Inertsil ODS-3V column (250 ×
4.6, i.d. 5 µm) was from Shimadzu (Tokyo, Japan).
2.3. Experimental design and sample collection
The animals were randomly divided into 3 groups (n =
5, each group). Before intravenous (i.v.) administrations,
restraint devices were applied to the auricular vein of each
animal. LPS (E. coli 0111:B4, Sigma) was then administered
to the 3 groups as a bolus i.v. injection (100 µg/kg b.w.).
After 1 h, the blood samples (2 mL) were collected from the
restraint devices for the control (at 0 min). FF (Nuflor) was
then dissolved in an organic solvent (dimethyl formamide)
and FF (20 mg/kg b.w.) was injected in the auricular vein
of animals via bolus i.v. in Group I (FF-LPS). FF (20 mg/kg
b.w.) and FM (2 mg/kg b.w.) were administered to Group
II (FF-FM-LPS). FF (20 mg/kg b.w.) and TN (1 mg/kg
b.w.) were administered to Group III (FF-TN-LPS) via the
same routes, simultaneously. Blood samples (2 mL) were
taken from each rabbit and collected in tubes containing
heparin as the anticoagulant at 5, 10, 15, 30, 45, 60, and
90 min and 2, 4, 6, 8, and 12 h after drug administrations.
They were centrifuged within 1 h after the collection and
plasma was separated after centrifugation for 10 min at
2000 rpm. Plasma samples were stored at –20 °C until
analysis. All of the samples were analyzed within 1 week
of the experiments.

2.4. Analytical procedure
FF was determined in plasma samples by HPLC (Shimadzu
20A Prominence System) with DAD (224 nm) using a
previously published method (18). CP was used as the
internal standard. Samples were analyzed by an Inertsil
ODS-3V column (250 × 4.6, i.d. 5 µm). The mobile phase
consisted of a mixture of acetonitrile-ammonium acetate
at a ratio of 20:80 (v/v). The injection volume was 100 µL,
the monitoring wavelength was 224 nm, the flow rate was
1.5 mL/min, and the oven temperature was 35 °C.
2.5. Extraction procedure
The procedure was performed as described by Koc et al.
(18). Briefly, the frozen plasma samples (0.25 mL) were
thawed at a room temperature, and then 0.75 mL of
water and 0.5 mL of internal standard (CP) were added
to spike the samples. These samples were extracted by
a solid phase extraction cartridge (C18, 3 mL, 500 mg,
Bond Elut, Agilent). The cartridge was conditioned with
methanol and water (v/v, 3 mL/3 mL). The mixture was
vortexed and transferred to a C18 cartridge. The cartridge
was then washed with a mixture of acetonitrile-water (2
mL, 15/85) and 3 mL of hexane. An eluate was collected
with acetonitrile (3 mL). The eluate was evaporated at 50
°C under a stream of nitrogen. The residue was dissolved
in the mobile phase and 100 μL of it was injected into the
HPLC system for analysis.
2.6. Validation
The validation parameters (linearity, precision [relative
standard deviation (RSD)], accuracy, limit of detection
(LOD), limit of quantitation (LOQ), recovery, and
reproducibility) were determined for the method. For
linearity, a calibration curve was calculated from 6
different levels (0.1–25.0 µg/mL) of FF automatically
using software. The inter- and intraday precisions were
calculated with 6 replicated analyses of spiked samples
with 3 different levels (0.1, 5, and 10 μg/mL) of FF on
the same and separate days. LOD was calculated to be 3
times the signal-to-noise ratio in the plasma samples when
spiking at low concentrations. LOQ was calculated to be
10 times the signal-to-noise ratio. The recoveries and the
inter- and intraday reproducibility were determined after
spiking from 0.1 to 10 µg/mL with 3 different levels of FF.
The calibration curve provided excellent linearity with
correlation coefficients (r2) of >0.9998 in the present study.
The inter- and intraday precision levels (RSD) were <7.0.
The mean recovery was 91.2 ± 5.13% and LOD and LOQ
were 0.01 and 0.03 µg/mL, respectively. There was a high
degree of reproducibility for FF.
2.7. Pharmacokinetic analysis
The noncompartmental model independent analysis, based
on the statistical moment theory, was applied to determine
the pharmacokinetic parameters for each individual
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D
t
%T > MIC = ln (
)x ( 1/2 ) x
Vdarea x MIC
ln (2)

(

100
DI

),

where T > MIC is the time interval (in percent) during
which the plasma concentration is above or equal to MIC
values, D is the proposed dose, Vdarea is the volume of
distribution (L), t1/2 is the terminal elimination half-life
(h), and DI is the dose interval (h) (19).
MIC90 values (0.25–2 µg/mL) reported for the most
relevant pathogens (Pasteurella multocida and Bordetella
bronchiseptica) that cause infection in rabbits were
compared with the plasma-concentration time curves and
kinetic parameters obtained in order to establish optimal
dosing regimens (20,21).
2.8. Statistical analysis
Data were analyzed using SPSS 16.0 (SPSS Inc., Chicago,
IL, USA). Mean residence time (MRT) and terminal halflife (t1/2λz) were compared between groups by means of the
Mann–Whitney U test. The other pharmacokinetic data
were analyzed using one-way analysis of variance, followed
by the Duncan test. Results are given as mean ± SD.

3. Results
The plasma concentration-time profile of FF was described
using a noncompartmental open model in LPS-induced
endotoxemic rabbits. After i.v. administrations to animals
at a single dose (20 mg/kg b.w.) of FF in the FF-LPS (alone),
FF-FM-LPS, and FF-TN-LPS groups, pharmacokinetic
data and plasma concentration-to-time curves of FF were
obtained as depicted in Table 1 and the Figure, respectively.
The t1/2λz, the area under the curve (AUC(0–12)), the MRT
and the volume of distribution at steady state (Vss) of FF
were significantly increased, whereas total body clearance
(ClT) was decreased in both the FF-FM-LPS and FF-TNLPS groups (coadministered) compared to the FF-LPS
(alone) group (P < 0.05, Table 1).
10.00

Concentration (µg/mL)

rabbit using a computerized program, WinNonlin version
4.01 (Pharsight Corporation, Scientific Consulting Inc.,
Raleigh, NC, USA).
To verify the time when the plasma drug concentration
stayed above or was equal to the minimal inhibitory
concentration (MIC) value, the following formula was
applied:

1.00

FF-LPS
FF+FM+LPS

0.10

0.01

FF+TN+LPS

0

2

4

6
8
Time (hour)
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Figure. Plasma concentrations of florfenicol (20 mg/
kg b.w.) following intravenous single administration and
coadministration with flunixin meglumine and tenoxicam in
LPS-induced endotoxemic rabbits.

Table 1. Mean ± SD pharmacokinetic parameters of florfenicol (20 mg/kg b.w.) following intravenous single
administration and coadministration with flunixin meglumine and tenoxicam in LPS-induced endotoxemic rabbits.
Parameter

Unit

FF-LPS

FF-FM-LPS

FF-TN-LPS

λz

1/h

0.26 ± 0.03a

0.19 ± 0.03b

0.16 ± 0.01b

t1/2λz (HM)

h

2.69 ± 0.38b

3.61 ± 0.56a

4.26 ± 0.32a

AUC(0–12)

h × µg/mL

34.44 ± 2.62b

37.75 ± 2.24a

40.38 ± 1.94a

ClT

mL h–1 kg–1

559.76 ± 44.66a

483.48 ± 22.51b

440.47 ± 26.68b

AUMC(0–12)

h × h × µg/mL

96.37 ± 15.51b

120.76 ± 12.41a

135.43 ± 9.74a

MRT (HM)

h

2.77 ± 0.24b

3.19 ± 0.20a

3.35 ± 0.10a

Vss

L/kg

1.85 ± 0.12b

2.16 ± 0.26a

2.21 ± 0.06a

Vd

L/kg

2.20 ± 0.28b

2.57 ± 0.40ab

2.71 ± 0.13a

: Different letters in the same line are statistically significant (P < 0.05). FF-LPS, florfenicol alone; FF-FM-LPS,
florfenicol coadministrated with flunixin meglumine; FF-TN-LPS, florfenicol coadministrated with tenoxicam; λz, the
first-order rate constant associated with the terminal portion of the curve; t1/2λz, terminal half-life; AUC(0–12), area under
the curve from time 0 to the last detectable concentration; ClT, total body clearance; AUMC(0–12), area under the first
moment curve; MRT, mean residence time; Vss, volume of distribution at steady state; HM, harmonic mean.
a, b, c
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Calculated %T > MIC results using the MIC values and
the calculated kinetic data (PK) are presented in Table 2.
At 8-, 12-, and 24-h intervals, FF following i.v. injection at
a dose of 20 mg/kg b.w. for bacteria with MIC values of ≤2
µg/mL maintained a T > MIC value of or above 73%, 49%,
and 24%, respectively, in all groups.
4. Discussion
In the present study, the plasma pharmacokinetic profile
for FF was described by a noncompartmental open model.
Until now, the best described models for this drug in
rabbits was noncompartmental (11,12) except in only one
study (13). The obtained result was in agreement with
previous reported studies in rabbits.
In published studies, the ClT of FF was reported from
0.56 to 0.63 L kg–1 h–1 (13,12). In the present study, this value
was 559.76 ± 44.66 L kg–1 h–1 in the FF-LPS (alone) group.
The obtained value was similar to the above reports for

administration of FF alone in healthy rabbits. In this study,
the ClT of the FF-LPS group was higher than in the FF-FMLPS (483.48 ± 22.51 L kg–1 h–1) and FF-TN-LPS (440.47 ±
26.68 L kg–1 h–1) groups. These differences in the ClT may
be related to both the prostaglandin inhibitory effects of
NSAIDs (FM and TN) and LPS-induced endotoxemia. It
is known that NSAIDs have an influence on the kinetic
disposition of some drugs. They may alter renal excretion
via prostaglandin inhibitory effects (9). This is because the
prostaglandins have a vasodilatory effect on blood vessels.
Renal blood flow is thus slowed and renin release is altered
by renal prostaglandins in the kidneys (22). In addition,
endotoxin has some negative effects on the kidneys, such
as direct vascular damage (endothelium and platelet
aggregation) in renal glomerular capillaries. Tubular cell
damage may be the result of effects of LPS. It also produces
some functional changes, including a slow in the renal
blood flow and glomerular filtration, and changes in the

Table 2. Calculated %T > MIC for florfenicol based on the pharmacokinetic parameters
obtained after intravenous single administration and coadministration of florfenicol
(20 mg/kg b.w.) with flunixin meglumine and tenoxicam in LPS-induced endotoxemic
rabbits for 8-, 12-, and 24-h dosing intervals.

%T > MIC

Dose interval
8h

12 h

24 h

FF-LPS

174

116

58

FF-FM-LPS

224

149

75

FF-TN-LPS

260

173

87

FF-LPS

141

94

47

FF-FM-LPS

179

119

60

FF-TN-LPS

207

138

69

FF-LPS

107

71

36

FF-FM-LPS

134

89

45

FF-TN-LPS

153

102

51

FF-LPS

73

49

24

FF-FM-LPS

88

59

29

FF-TN-LPS

100

67

33

MIC 0.25 µg/mL

MIC 0.5 µg/mL

MIC 1 µg/mL

MIC 2 µg/mL

%T > MIC has been calculated for MICs of 0.25, 0.5, 1, and 2 µg/mL on the basis of
reported MIC90s (0.25–2 µg/mL) for Pasteurella multocida and Bordetella bronchiseptica
(20,21). MIC: Minimal inhibitory concentration.
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hemodynamics in the kidney. As a result, endotoxin has
an important role in the decrease of the body clearance of
drugs that are widely eliminated by the renal route (23,24).
It has been reported that FF was excreted in urine as the
parent form (64%) and as component parts of FF (5).
In the present study, t1/2λz was 2.69 ± 0.38 h, 3.61 ± 0.56
h, and 4.26 ± 0.32 h in the FF-LPS, FF-FM-LPS, and FFTN-LPS groups, respectively. The obtained results were
significantly increased in the FF-FM-LPS (3.61 ± 0.56 h) and
FF-TN-LPS (4.26 ± 0.32 h) groups (coadministered) when
compared with the FF-LPS group (alone) in the present
study. In addition, these parameters were significantly
increased and inconsistent with the results of reported
studies (11–13) in healthy rabbits. In the present study, the
AUC(0–12) was somewhat similar to that of a previous study
(13) after administration of FF in healthy rabbits. However,
this value slightly increased in coadministration of FFFM-LPS and FF-TN-LPS when compared with FF-LPS
in animal groups. As a result, increasing the AUC(0–12) and
lengthening the t1/2λz may be related to decreasing the ClT
of FF in coadministered groups in endotoxemic rabbits. In
our study, the Vss of FF was large (from 1.85 ± 0.12 to 2.21 ±
0.06 L/kg). These results were inconsistent with the results
(from 0.57 ± 0.85 to 0.98 ± 0.05 L/kg) of previous studies
(11–13) in healthy rabbits. The Vss significantly altered in
coadministration of LPS-induced rabbits. The large size of
the Vss may be related to both the lipophilicity of the drug
and endotoxemia. The MRTs of FF in the present study
were not similar to those of previous studies (11–13) in
healthy rabbits. The MRT was longer in coadministered
endotoxemic rabbits. The greater lengths of the t1/2λz and
the MRT are important due to the residues of drugs in
coadministration. In further studies, the withdrawal time
of FF may be altered in coadministered animals.
Drug interaction is a common phenomenon in
pharmacology. There are many reports about this
phenomenon in different species. In previous studies, the
pharmacokinetics of FF were altered by the combination of
FF and tylosin in dogs (16), FF-anthelmintics combination
in goats (15), and FF-polyether ionophore combination
in broilers (17). The result of our study was in agreement
with the results of the above reported studies. Liu et al.
(25) reported that there was no statistically significant
difference between the pharmacokinetic profiles of FF for
pigs infected with Actinobacillus pleuropneumoniae and
healthy pigs. On the other hand, it was reported that there
was a decrease in the elimination half-life and the apparent
volume of distribution of FF in healthy and Escherichia
coli-infected broiler chickens (26).
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FF acts as a time-dependent bactericidal drug (27).
The most important pharmacodynamic/pharmacokinetic
parameter for a time-dependent drug is the length of
the time above the MIC90 value (19,28,29). It is generally
recommended that T > MIC should be at least 40% of
the dosage interval. It has also been reported that plasma
concentrations of drugs in critically ill patients should
exceeded MIC90 values for 80% of the time between two
consecutive applications (30). The MICs of FF for bacteria
isolated from rabbits have not yet been determined. The
in vitro efficacy of FF against Pasteurella multocida and
Bordetella bronchiseptica isolated from pigs and cattle has
been demonstrated by various studies (20,21). Considering
the reported MIC90 (0.25–2 µg/mL) for Pasteurella
multocida and Bordetella bronchiseptica (20,21), which
cause infection in rabbits, the T > MIC has been calculated
for MICs of 0.25, 0.5, 1, and 2 µg/mL. Results show that
at 8-, 12-, and 24-h intervals, FF following i.v. injection at
a dose of 20 mg/kg b.w. for bacteria with MIC values of
≤2 µg/mL maintains T > MIC above 73%, 49%, and 24%,
respectively, in all groups. In this study, because the rabbits
are critically ill, T > MIC for FF should be above 80% in
the time between two consecutive applications. When the
experimental data presented here are evaluated according
to T > MIC above 80%, the results show that FF at a dose
of 20 mg/kg b.w. intravenously administered is sufficient
to maintain T > MIC at above 88% for bacteria with MIC
values of ≤2 µg/mL at 8-h intervals and above 89% for
bacteria with MIC values of ≤1 µg/mL at 12-h intervals
with the administration of FM and TN, and above 87% for
bacteria with MIC values of ≤0.25 µg/mL at 24-h intervals
with the administration of TN only.
In conclusion, FM and TN affected the pharmacokinetic
profile of FF when FF, FM, or TN were coadministered in
endotoxemic rabbits. Due to their effects, the adjustment
of the dosage regimens of FF should be considered.
Because the dose regimen suggested in the present study
meets the pharmacokinetic/pharmacodynamic criteria
in predicting a successful therapy for susceptible bacteria
with an MIC of ≤2 µg/mL, it may be considered for clinical
use in critically ill rabbits. However, the dosage regimen
of FF may be altered according to the pharmacodynamic
parameters determined from the pathogens of rabbit
origin, the pharmacokinetic parameters obtained in large
populations, and the replacement therapy in critically
ill rabbits. Further studies are necessary to determine
variations in dosage regimens.
Acknowledgment
We thank Atatürk University, Erzurum, Turkey (Veterinary
Faculty and Experimental Research Center) for its support.

KOÇ et al. / Turk J Vet Anim Sci

References
1.

Mayeux PR. Pathobiology of lipopolysaccharide. J Toxicol
Environ Health 1997; 51: 415–435.

2.

Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet
2005; 365: 63–78.

3.

16.

Kim EY, Gebru E, Lee JS, Kim JC, Park SC. Pharmacokinetics
of a florfenicol-tylosin combination after intravenous and
intramuscular administration to beagle dogs. J Vet Med Sci
2011; 73: 463–466.

Redl H Bahrami S, Schlag G, Traber DL. Clinical detection
of LPS and animal models of endotoxemia. Immunobiology
1993; 187: 330–345.

17.

Wang G, Tu P, Chen X, Guo YG, Jiang SX. Effect of three
polyether ionophores on pharmacokinetics of florfenicol in
male broilers. J Vet Pharmacol Ther 2013; 36: 494–501.

4.

Elmas M, Yazar E, Uney K, Er Karabacak A. Pharmacokinetics
of flunixin after intravenous administration in healthy and
endotoxaemic rabbits. Vet Res Commun 2006; 30: 73–81.

18.

5.

Papich MG, Riviere JE. Chloramphenicol and derivatives,
macrolides, lincosamides and miscellaneous antimicrobials. In:
Adams HR, editor. Veterinary Pharmacology and Therapeutics.
8th ed. Ames, IA, USA: Iowa State University Press; 2001. pp.
868–897.

Koc F, Atila A, Karakus E, Cetin N. Determination of
florfenicol in plasma of rabbits by high-performance liquid
chromatography after solid phase extraction. J Vet Pharmacol
Ther 2012; 35: 89–89.

19.

Turnidge JD. The pharmacodynamics of beta-lactams. Clin
Infect Dis 1998; 27: 10–22.

20.

Priebe S, Schwarz S. In vitro activities of florfenicol against
bovine and porcine respiratory tract pathogens. Antimicrob
Agents Chemother 2003; 47: 2703–2705.

21.

Kehrenberg C, Mumme J, Wallmann J, Verspohl J, Tegeler R,
Kühn T, Schwarz S. Monitoring of florfenicol susceptibility
among bovine and porcine respiratory tract pathogens
collected in Germany during the years 2002 and 2003. J
Antimicrob Chemother 2004; 54: 572–574.

22.

Dunn MJ, Hood VL. Prostaglandins and the kidney. Am J Phys
Ren Phys 1977; 233: 169–184.

23.

Hasegawa T, Takagi K, Kitaichi K. Effects of bacterial endotoxin
on drugs pharmacokinetics. Nagoya J Med Sci 1999; 6: 11–28.

6.

Zhang X, Song K, Xiong H, Li H, Chu X, Deng X. Protective
effect of florfenicol on acute lung injury induced by
lipopolysaccharide in mice. Int Immunopharmacol 2009; 9:
1525–1529.

7.

Anderson KL, Smith AR, Shanks RD, Davis LE, Gustafsson BK.
Efficacy of flunixin meglumine for the treatment of endotoxininduced bovine mastitis. Am J Vet Res 1986; 47: 1366–1372.

8.

Van Donkersgoed J, Berg J, Hendrick S. A comparison of
florfenicol-flunixin meglumine versus tulathromycin for the
treatment of undifferentiated fever in fall-placed feedlot calves.
Vet Ther 2009; 10: 78–85.

9.

Verbeeck RK. Pharmacokinetic drug interactions with
nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet
1990; 19: 44–66.

24.

Yang KH, Lee MG. Effects of endotoxin derived from
Escherichia coli lipopolysaccharide on the pharmacokinetics of
drugs. Arch Pharm Res 2008; 31: 1073–1086.

10.

Li JZ, Fung KF, Chen ZL, Zhang J. Tissue pharmacokinetics of
florfenicol in pigs experimentally infected with Actinobacillus
pleuropneumoniae. Eur J Drug Metab Pharmacokinet 2002; 27:
265–271.

25.

Liu J, Fung KF, Chen Z, Zeng Z, Zhang J. Pharmacokinetics of
florfenicol in healthy pigs and in pigs experimentally infected
with Actinobacillus pleuropneumoniae. Antimicrob Agents
Chemother 2003; 47: 820–823.

11.

El-Aty AM, Goudah A, El-Sooud KA, El-Zorba HY, Shimoda
M, Zhou HH. Pharmacokinetics and bioavailability of
florfenicol following intravenous, intramuscular and oral
administrations in rabbits. Vet Res Commun 2004; 28: 515–
524.

26.

Shen J, Wu X, Hu D, Jiang H. Pharmacokinetics of florfenicol
in healthy and Escherichia coli-infected broiler chickens. Res
Vet Sci 2002; 73: 137–140.

27.

Park BK, Lim JH, Kim MS, Hwang YH, Yun HI.
Pharmacokinetics of florfenicol and its major metabolite,
florfenicol amine, in rabbits. J Vet Pharmacol Ther 2007; 30:
32–36.

AliAbadi FS, Lees P. Antibiotic treatment for animals: effect on
bacterial population and dosage regimen optimisation. Int J
Antimicrob Agents 2000; 14: 307–313.

28.

Koc F, Ozturk M, Kadioglu Y, Dogan E, Yanmaz LE, Okumus
Z. Pharmacokinetics of florfenicol after intravenous and
intramuscular administration in New Zealand White rabbits.
Res Vet Sci 2009; 87: 102–105.

Craig WA. Interrelationship between pharmacokinetics and
pharmacodynamics in determining dosage regimens for
broad-spectrum cephalosporins. Diagn Microbiol Infect Dis
1995; 22: 89–96.

29.

14.

Koc F, Uney K, Ozturk M, Kadioglu Y, Atila A. Pharmacokinetics
and bioavailability of florfenicol in the plasma of Japanese
quails. New Zeal Vet J 2009; 57: 388–391.

McKellar QA, Sanchez Bruni SF, Jones DG. Pharmacokinetic/
pharmacodynamic relationships of antimicrobial drugs used in
veterinary medicine. J Vet Pharm Therap 2004; 27: 503–514.

30.

15.

Atef M, El-Gendi AY, Amer AM, El-Aty AM. Effect of three
anthelmentics on disposition kinetics of florfenicol in goats.
Food Chem Toxicol 2010; 48: 3340–3344.

Toutain PL, Del Castillo JRE, Bousquet-Melou A. The
pharmacokinetic-pharmacodynamic approach to a rational
dosage regimen for antibiotics. Res Vet Sci 2002; 73: 105–114.

12.

13.

173

